The UK Renal Registry (UKRR) was established by
the Renal Association to act as a resource in the development of patient care in renal disease. 1.2 The Registry acts as a source of comparative data for audit, benchmarking, planning, policy and research. The collection and analysis of sequential biochemical and haematological data is a unique feature of the UKRR.
The Renal Registry Data Set Specification (RRDSS)
defines the data items that are required to be sent from participating renal centres for analysis by the UKRR. 1. 4 Data is collected quarterly to maintain centre-level quality assurance, with the results being published in an annual report. 1.5 Activity is funded from commissioning agencies by a capitation fee on renal patients. 4 Together with the need to know demographic and structural elements, the NHS has developed a need to underpin clinical activity more rigorously through the scientific evidence base (for example, the Cochrane Initiative) and by quality assurance activity through audit. These initiatives require comprehensive information about the structures, processes and outcomes of RRT, which go well beyond the detail previously compiled by the ERA-EDTA. 2.5 The Registry is recognised as one of the very few high quality clinical databases available for general use [6] . The collection of data by download of electronic records from routine clinical databases is uncommon, has been highly successful and is being imitated worldwide. 2. 6 The Renal Association has made a start in the area of audit by publishing guidelines in renal 'Clinical Standards' documents. It was apparent during the development of the standards that many of the desirable criteria of clinical performance were uncertain or unknown and that only the accumulated data of practicing renal centres could provide the evidence for advice on best practice and what might be achievable. A common data registration provides the simplest device for such an exercise. The data currently gathered audits a proportion of the Renal Association standards, partly due to some data items required not being available in the dataset and partly due to data not being either completed in or extracted from renal systems. There therefore needs to be a review of the dataset and a drive for more complete data returns by renal centres. 2.7 It can be seen that the need for a Registry of RRT has developed for a variety of reasons: international comparisons, national planning, local Trust and health authority management, standard setting, audit and research. The opportunity for data gathering arises partly from improvements in information technology. Although it was possible to see the need for a national renal database 20 years ago, the circumstances have become ideal for the maintenance of a data repository, supported by the clinical users and resourced for national benchmarking as a routine part of RRT management.
The provisional expectations of earlier Annual
Reports can now be replaced by confident assertions, built on the experience of fifteen years of publication, about the role and potential of the UKRR. The integration of the various elements of Renal Association strategy is being pursued through the Clinical Affairs Board (CAB).
A:3 Statement of intent
The Renal Registry provides a focus for the collection and analysis of standardised data relating to the incidence, clinical management and outcome of renal disease. Data will be accepted quarterly by automatic downloading from renal centre databases. There will be a core dataset, with optional elements of special interest that may be entered by agreement for defined periods. A report will be published annually to allow a comparative audit of facilities, patient demographics, quality of care and outcome measures. Reports using the data collected can be generated at centre, regional and national level by interested parties via the data portal on the UKRR website www.renalreg.com. Participation is mandated in England through the recommendation in the Renal National Service Framework. There has been an early concentration on RRT, including transplantation, with an intention to extend this to other nephrological activity in the near future. The Registry will provide an independent source of data and analysis on national activity in renal disease. of sufficiently widespread interest for the UKRR to undertake. 6.7 The database has been designed to provide research facilities and for future participation in national and international trials. Members of the Renal Association and other interested parties are welcome to apply to the Registry Study Groups to conduct local or national audit and research using the database. All such projects will need the agreement of the Registry Study Groups and any costs involved may need to be met by the applicants. 6.8 These facilities will be sustainable only through cooperation between nephrologists and the UKRR. There is a need for high-quality and comprehensive data entry at source. 6.9 Centres will need to develop an 'annual informatics plan', to review the maintenance and improvement of data collection, organisation and returns to the UKRR. This will help maintain the accuracy, timeliness and completeness of clinical data and also in parallel, support the career development of informatics staff.
A:7 The role of the UK Renal Registry for Trust managers 7.1 As the basis of the clinical governance initiative, the gathering and presentation of clinical data are regarded as essential parts of routine patient management in the health service. 7.2 One of the principles of health service informatics is that the best data are acquired from clinical information recorded at the point of health care delivery. 7.3 Renal services data entered on local systems by staff directly engaged with patients are likely to be of the highest quality and it is these that the UKRR intends to capture. 7. 4 The UKRR provides a cost-effective source of detailed information on renal services. 7.5 The regular reports of the UKRR supply details of patient demographics, treatment numbers, treatment quality and outcomes. Data are compared with both national standards and national performance, for benchmarking and quality assurance. The assessment of contract activity and service delivery is possible through these data returns, without the need for further costly Trust or commissioner administrative activity. These data should be particularly valuable to contracts managers and those responsible for clinical governance. 7.6 Data are available on centre case mix, infrastructure and facilities. 7.7 Work is progressing on the data capture and analysis from patients with renal disease other than those requiring RRT and will become available in time (e.g. chronic kidney disease and acute kidney injury).
A:8 The role of the UK Renal Registry for Commissioners of health care
8.1 The commissioning of healthcare within England is evolving again providing uncertainty around the arrangements. However, from meetings with commissioners it is apparent however the powerful role accurate data plays in their decisions. 8.2 The use of information sources such as the UKRR is advised in the National Renal Review in order to promote benchmarking and quality assurance of renal programmes. The comprehensive tracking of relatively small but costly renal cohorts should be regarded as a routine part of speciality case management. 8.3 The UKRR provides validated, comparative reports of renal centre activity on a regular basis to participating centres. These allow assessment of centre performance across a wide range of variables relating to structure, process and outcome measures. 8. 4 There are economies of scale in the performance of audit through the UKRR, since multiple local audits are not required. 8.5 The incidence of RRT treated locally, mortality and renal transplant rates should also be of interest. The assessment of referral and treatment patterns of patients with established (end stage) renal failure by postcode analysis indicates the geographical origin. This information also allows the expression of differences relating to geography, ethnicity and social deprivation. These data may also identify potential unmet need in the population and permit assessment on the equity of service provision. In the future, the UKRR database should also provide information on nephrology and pre-dialysis patients (CKD). This will allow a prediction of the need for RRT facilities, as well as indicating the opportunities for beneficial intervention.
8.6 UKRR data are used to track patient acceptance and prevalence rates over time, which allows the modelling of future demand and the validation of these predictions. 8.7 Information on the clinical diagnosis of new and existing RRT patients may help identify areas where possible preventive measures may have maximal effect. 8.8 The higher acceptance rates in the elderly, and the increasing demand from ethnic groups due to a high prevalence of renal, circulatory and diabetic disease, are measurable. 8.9 Comparative data are available in all categories for national and regional benchmarking. 8.10 The UKRR offers independent expertise in the analysis of renal services data and their interpretation, a resource that is widely required but difficult to otherwise obtain. 8.11 In 2014 the cost of supporting the UKRR will be £19 per registered RRT patient per annum (no change from 2013), which is less than 0.05% of the typical cost of a dialysis patient per annum. It is expected that this cost will need to be made explicit within the renal services contract.
A:9 The role of the UK Renal Registry for national quality assurance agencies 9.1 The role of the UKRR in the national quality assurance programme of the Healthcare Quality Improvement Partnership, will depend on the decisions on the role and responsibilities of that agency and their means to discharging them. 9.2 The demographic, diagnostic and outcomes data could support the investigation of clinical effectiveness. 9.3 The case mix information and comorbidity data that would allow better assessment of survival statistics remains incomplete. There is also some clinical scepticism whether 'correction' of outcome data would reflect the realities of clinical practice.
